XKRX
023910
Market cap99mUSD
Jul 10, Last price
25,950.00KRW
1D
1.76%
1Q
-9.27%
Jan 2017
-6.82%
Name
DaehanPharmaceutical
Chart & Performance
P/E
—
P/S
—
EPS
Div Yield, %
3.53%
Shrs. gr., 5y
—
Rev. gr., 5y
6.31%
Revenues
Net income
CFO
Dividend
Dec 29, 2025900 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As a pioneer in Korea's pharmaceutical landscape, Daihan Pharmaceutical Co., Ltd. was the first to produce infusions, a crucial innovation that significantly contributed to national public health. This initial achievement not only forged new pathways for other medical companies but also solidified its standing as a leading domestic manufacturer of intravenous solutions.
Valuation
Title KRW in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |